Babesia microti Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis

Abstract We report Babesia microti genomic sequences with multiple mutations in the atovaquone-target region of cytochrome b, including a newly identified Y272S mutation, plus 1 mutation of undetermined significance in the azithromycin-associated ribosomal protein L4. The parasite was sequenced from an immunocompromised patient on prophylactic atovaquone for Pneumocystis pneumonia before diagnosis of babesiosis.

[1]  P. Krause,et al.  Broad antimicrobial resistance in a case of relapsing babesiosis successfully treated with tafenoquine. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Wormser,et al.  Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone , 2022, IDCases.

[3]  A. Paniz‐Mondolfi,et al.  Relapsed Babesia microti Infection Following Allogeneic Hematopoietic Cell Transplantation in a Patient With B-cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature , 2021, Open forum infectious diseases.

[4]  Choukri Ben Mamoun,et al.  Cytochrome b Drug Resistance Mutation Decreases Babesia Fitness in the Tick Stages but not the Mammalian Erythrocytic Cycle. , 2021, The Journal of infectious diseases.

[5]  Raveendhara R. Bannuru,et al.  Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  P. Krause,et al.  Clofazimine, a promising drug for the treatment of Babesia microti infection in severely immunocompromised hosts. , 2020, The Journal of infectious diseases.

[7]  P. Krause,et al.  Repeat exchange transfusion for treatment of severe babesiosis. , 2019, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[8]  A. Schotthoefer,et al.  Risk Factors for Severe Infection, Hospitalization, and Prolonged Antimicrobial Therapy in Patients with Babesiosis. , 2017, The American journal of tropical medicine and hygiene.

[9]  L. Westblade,et al.  Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Pardis C. Sabeti,et al.  A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse , 2016, Nature Microbiology.

[11]  Trevor Bedford,et al.  Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone , 2015, Cell.

[12]  Wei-Chun Kao,et al.  Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action , 2014, Nature Communications.

[13]  H. Ranson,et al.  Cytochrome b Mutation Y268S Conferring Atovaquone Resistance Phenotype in Malaria Parasite Results in Reduced Parasite bc1 Catalytic Turnover and Protein Expression , 2012, The Journal of Biological Chemistry.

[14]  Samit R. Joshi,et al.  Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Ivo M Foppa,et al.  Persistent and relapsing babesiosis in immunocompromised patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Fidock,et al.  In Vitro Efficacy, Resistance Selection, and Structural Modeling Studies Implicate the Malarial Parasite Apicoplast as the Target of Azithromycin* , 2007, Journal of Biological Chemistry.

[17]  Q. Cheng,et al.  Mutations in Plasmodium falciparumCytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site , 2000, Antimicrobial Agents and Chemotherapy.

[18]  Joanne M. Morrisey,et al.  Resistance mutations reveal the atovaquone‐binding domain of cytochrome b in malaria parasites , 1999, Molecular microbiology.

[19]  M. Fry,et al.  Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). , 1992, Biochemical pharmacology.

[20]  F. Cox.  Human babesiosis , 1980, Nature.